Chlamydia Infections Clinical Trial
Official title:
Screening of Gonococcal and Chlamydial Infections in the Third Trimester
Untreated maternal infection with gonorrhea and/or chlamydia can have serious complications in pregnancy and the neonatal period. In Ontario, routine screening for these infections is done in the first trimester of pregnancy, positive cases are treated with antibiotics, and all newborns are given antibiotic eye ointment within 24 hours of birth. Recently, the Canadian Pediatric Society recommended stopping universal prophylaxis for newborns, with instead, focus on screening and treatment of these infections in pregnancy. Given that these infections can occur at any time in pregnancy, and exposure at delivery provides a significant risk to infants, more information is needed about the rates of infection throughout pregnancy and health-care provider compliance with guidelines to make this change without undue risk. With this information optimal timing of testing can be evaluated.
The primary objective of this study is to retrospectively examine the incidence rates of N.
gonorrhoeae (NG) and C. trachomatis (CT) in the first and third trimester for the obstetrical
population at St. Michael's Hospital over the course of six months. Secondary objectives
include (1) feasibility of instituting third trimester screening for sexually transmitted
infections, and (2) assessment of physician compliance with Canadian screening and treatment
guidelines. This information will help us to deduce the optimal timing of screening for NG
and CT in the obstetrical population at St. Michael's Hospital.
It is hypothesized that the incidence rates of both NG and CT infections will be low, but
that much can be learned from the positive cases in terms of risk factors and optimal timing
of screening. Further, the feasibility of screening in the third trimester will offer options
for future guidelines.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00381992 -
Risk Assessment of Long-Haul Truck Drivers
|
N/A | |
| Completed |
NCT00115388 -
Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease
|
N/A | |
| Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
| Completed |
NCT00207506 -
Lay Health Advisors for Sexually Transmitted Disease Prevention
|
Phase 1/Phase 2 | |
| Completed |
NCT00132457 -
Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection
|
N/A | |
| Terminated |
NCT00120770 -
Cellulose Sulfate (CS) Gel and HIV in Nigeria
|
Phase 3 | |
| Completed |
NCT00001890 -
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
|
Phase 2 | |
| Not yet recruiting |
NCT05727033 -
Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
|
N/A | |
| Completed |
NCT00561028 -
Chlamydia and Mycoplasma in Coronary Artery Disease
|
N/A | |
| Completed |
NCT00112255 -
Partner Notification for Chlamydia in Primary Care
|
Phase 3 | |
| Completed |
NCT00252096 -
Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections
|
N/A | |
| Completed |
NCT00037388 -
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
|
N/A | |
| Terminated |
NCT01728103 -
Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays
|
N/A | |
| Completed |
NCT00607659 -
Immunopathogenesis of Chlamydia
|
N/A | |
| Completed |
NCT00000120 -
Clinical Trial of Eye Prophylaxis in the Newborn
|
Phase 3 | |
| Completed |
NCT01638637 -
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
|
N/A | |
| Completed |
NCT03374696 -
Theater in School Sex Education - a Randomized Controlled Study
|
N/A | |
| Active, not recruiting |
NCT00124878 -
Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
|
Phase 3 | |
| Completed |
NCT00005547 -
Infection and Cardiovascular Disease
|
N/A |